Key points are not available for this paper at this time.
Ibrutinib is associated with higher risk of AF, bleeding, and HF, but not AMI or stroke.
Share your take
Add a clinician perspective alongside expert commentary.
Abdel‐Qadir et al. (Tue,) studied this question.